Fact or hypothesis: Taenia crassiceps as a model for Taenia solium, and the S3Pvac vaccine
- PMID: 21039610
- PMCID: PMC3033518
- DOI: 10.1111/j.1365-3024.2010.01231.x
Fact or hypothesis: Taenia crassiceps as a model for Taenia solium, and the S3Pvac vaccine
Abstract
Research undertaken over the past 40 years has established many of the general principals concerning immunity to taeniid cestodes. Although much is well understood about the host-protective mechanisms against taeniids and this knowledge has been exploited in studies on vaccine development, many aspects require further investigation or confirmation. Some phenomena have come to be regarded as being well established, while careful analysis of the published data would suggest that they may be better regarded as hypotheses rather than established facts. This review considers one selected issue pertaining to immunity to cestode infections and examines carefully the nature of the evidence that is available to support conclusions that have been made in this area. The issue examined is the use of Taenia crassiceps as a model for cysticercosis in pigs caused by Taenia solium, together with the S3Pvac vaccine, which has been developed based on this model. Strong evidence is found to support the conclusion that defined T. crassiceps antigens can limit intraperitoneal proliferation of the ORF strain of T. crassiceps in mice; however, the potential for these antigens to affect T. solium infection in pigs requires further confirmation.
© 2010 Blackwell Publishing Ltd.
Comment in
-
Taenia crassiceps as a model for Taenia solium and the S3Pvac vaccine.Parasite Immunol. 2011 Jan;33(1):79-80. doi: 10.1111/j.1365-3024.2010.01257.x. Parasite Immunol. 2011. PMID: 21155844 No abstract available.
Similar articles
-
Development of the S3Pvac vaccine against murine Taenia crassiceps cysticercosis: a historical review.J Parasitol. 2013 Aug;99(4):693-702. doi: 10.1645/GE-3101.1. Epub 2013 Feb 14. J Parasitol. 2013. PMID: 23409920 Review.
-
Development of the S3Pvac vaccine against porcine Taenia solium cysticercosis: a historical review.J Parasitol. 2013 Aug;99(4):686-92. doi: 10.1645/GE-3102.1. Epub 2013 Feb 27. J Parasitol. 2013. PMID: 23445359 Review.
-
Transgenic papaya: a useful platform for oral vaccines.Planta. 2017 May;245(5):1037-1048. doi: 10.1007/s00425-017-2658-z. Epub 2017 Feb 13. Planta. 2017. PMID: 28194565
-
Synthetic peptide vaccine against Taenia solium pig cysticercosis: successful vaccination in a controlled field trial in rural Mexico.Vaccine. 2001 Oct 12;20(1-2):262-6. doi: 10.1016/s0264-410x(01)00249-3. Vaccine. 2001. PMID: 11567772 Clinical Trial.
-
Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis.Vaccine. 2008 Jun 2;26(23):2899-905. doi: 10.1016/j.vaccine.2008.03.042. Epub 2008 Apr 10. Vaccine. 2008. PMID: 18440675
References
-
- Lightowlers MW. Cestode vaccines: origins, current status and future prospects. Parasitology. 2006;133:S27–S42. - PubMed
-
- Rickard MD, Williams JF. Hydatidosis/cysticercosis: immune mechanisms and immunization against infection. Adv Parasitol. 1982;21:229–296. - PubMed
-
- Gemmell MA. Species specificity of the immunogenic complexes of the tapeworm hexacanth embryo. Nature. 1964;204:705–707. - PubMed
-
- Sciutto E, Rosas G, Hernandez M, et al. Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine. Vaccine. 2007;25:1368–1378. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous